EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer

Peng Liu, Haocheng Zhang, Yuhang Qian iD, Jiong Zhang, Xiaojun Deng, Bin Sun

Journal of Biochemical and Molecular Toxicology · 2026

DOI: 10.1002/jbt.71080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Peng Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, 411 Hospital of Shanghai University, Shanghai, China. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Drug Resistance, Neoplasm, Ferroptosis, Prostatic Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Project of Hongkou District Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) remains a leading cause of cancer‐related mortality in aging male, with resistance to enzalutamide (Enza) representing a major therapeutic challenge. This study identifies SLC3A1 as a key driver of Enza resistance. Through integrative bioinformatics analysis of GEO datasets, we found SLC3A1 significantly upregulated in Enza‐resistant PCa models. WGCNA and single‐cell RNA sequencing confirmed its association with adverse prognosis and activation of key survival pathways. Functional experiments demonstrated that SLC3A1 knockdown reduced AKT phosphorylation, and inhibited colony formation in LNCaP cells. Conversely, SLC3A1 overexpression activated PI3K‐AKT signaling, suppressed ferroptosis and conferred Enza resistance in vitro and in vivo. These results reveal SLC3A1 is a promising therapeutic target for advanced prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinDrug Resistance, NeoplasmFerroptosisProstatic NeoplasmsAmino Acid Transport Systems, BasicNeoplasm ProteinsMaleHumansNitrilesBenzamidesAnimalsCell Line, TumorMiceSignal Transduction

Stichwörter der Autor:innen

GEOSLC3A1WGCNAenzalutamideprostate cancer

Substanzen

enzalutamideNitrilesPhenylthiohydantoinBenzamidesAmino Acid Transport Systems, BasicNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Urology, 411 Hospital of Shanghai University, Shanghai, China.

ORCID-Profile: Yuhang Qian

Förderung

  • Medical Research Project of Hongkou District Health Commission

Zitieren

APA

Liu, P., Zhang, H., Qian, Y., Zhang, J., Deng, X., & Sun, B. (2026). SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.71080

Vancouver

Liu P, Zhang H, Qian Y, Zhang J, Deng X, Sun B. SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.71080

BibTeX
@article{Liu2026,
  author = {Liu, Peng and Zhang, Haocheng and Qian, Yuhang and Zhang, Jiong and Deng, Xiaojun and Sun, Bin},
  title = {SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2026},
  doi = {10.1002/jbt.71080}
}
Kostenlos starten →